Javascript must be enabled to continue!
P1558Clinical utility of the PRECISE-DAPT score in the prediction of hemorrhagic events in elderly patients with acute coronary syndrome
View through CrossRef
Abstract
Introduction
The clinical utility and validity of the PRECISE-DAPT bleeding risk score for elderly patients with acute coronary syndrome (ACS) is unknown. We investigated the previous aspect in a contemporary population treated with percutaneous coronary intervention (PCI) and dual antiplatelet therapy (DAPT) at discharge.
Methods
Retrospectively, from 2010 to 2016, we studied 3,814 consecutive patients with the diagnosis of ACS. All patients were treated with in-hospital PCI and DAPT at discharge. Elderly was defined if patients aged ≥75 years. Patients were categorized into three risk strata according to their PRECISE-DAPT score (very low-low: <17 points, moderate: 18–24 points, and high risk: ≥25 points). We included the first bleeding event occurred during the first year after discharge. Bleeding events were defined according to the BARC classification system, and divided into two subgroups: BARC 2–5 and BARC 3–5. The ability to separate high bleeding risk patients from lower bleeding risk patients was checked by the cumulative incidence function curves and compared using the Fine-Gray test, thus adjusting for death (non-bleeding related) as a competing risk. Discrimination (C statistic) and calibration (Hosmer-Lemeshow test) were used to test the predictive capacity of the score in pts aged ≥75 years and <75 years.
Results
25.2% (n=961/3814) were ≥75 years old, 38.4% of them were women. DAPT duration was 11.5 (interquartile range [IQR] 2.5–13.7) vs. 12.0 (RIQ 8.2–14.1) months in the elderly vs. younger; (p<0.001). 92.5% (n=889) of the elderly were at high risk of bleeding (PRECISE-DAPT≥25 points), compared to 21.3% (n=607) of the youngest.
The incidence of BARC 2–5 and BARC 3–5 was 7.4% and 2.7% in the elderly compared to 5.1% and 1.4% among the younger patients (p<0.001). The figure shows the ability of the PRECISE-DAPT score at capturing the risk of BARC 2–5 bleeding (panel A and B), in both age groups.
Using the cut-off point ≥25, the effect in the prediction of BARC 2–5 bleeding and BARC 3–5 did not differ significantly between the elderly and those <75 years: sHR = 1.9 (95% CI: 1.2–6.00) in the elderly vs. 1.8 (95% CI: 1.3–2.5) in the other group (p=0.99) and sHR = 3.3 (95% CI: 1.9–6.0) vs. 3.6 (95% CI: 1.9–6.7) (p=0.83), respectively. There were no significant differences between the elderly and those under 75 years in terms of statistical C values either for BARC 2–5 bleeding (0.60 vs. 0.58) or BARC 3–5 bleeding (0.64 vs. 0.67). The score performed well in term of calibration in both groups (all p-values >0.3).
Conclusion
Although the use of PRECISE-DAPT resulted in classifying the majority of elderly patients at high risk of bleeding and despite exhibiting modest discriminative power, it performed well at classifying patients according to their risk of 1-year out-of-hospital bleeding in both age groups. PRECISE-DAPT appears to identify the truly low risk patients among the elderly, as compared to the younger group.
Oxford University Press (OUP)
Title: P1558Clinical utility of the PRECISE-DAPT score in the prediction of hemorrhagic events in elderly patients with acute coronary syndrome
Description:
Abstract
Introduction
The clinical utility and validity of the PRECISE-DAPT bleeding risk score for elderly patients with acute coronary syndrome (ACS) is unknown.
We investigated the previous aspect in a contemporary population treated with percutaneous coronary intervention (PCI) and dual antiplatelet therapy (DAPT) at discharge.
Methods
Retrospectively, from 2010 to 2016, we studied 3,814 consecutive patients with the diagnosis of ACS.
All patients were treated with in-hospital PCI and DAPT at discharge.
Elderly was defined if patients aged ≥75 years.
Patients were categorized into three risk strata according to their PRECISE-DAPT score (very low-low: <17 points, moderate: 18–24 points, and high risk: ≥25 points).
We included the first bleeding event occurred during the first year after discharge.
Bleeding events were defined according to the BARC classification system, and divided into two subgroups: BARC 2–5 and BARC 3–5.
The ability to separate high bleeding risk patients from lower bleeding risk patients was checked by the cumulative incidence function curves and compared using the Fine-Gray test, thus adjusting for death (non-bleeding related) as a competing risk.
Discrimination (C statistic) and calibration (Hosmer-Lemeshow test) were used to test the predictive capacity of the score in pts aged ≥75 years and <75 years.
Results
25.
2% (n=961/3814) were ≥75 years old, 38.
4% of them were women.
DAPT duration was 11.
5 (interquartile range [IQR] 2.
5–13.
7) vs.
12.
0 (RIQ 8.
2–14.
1) months in the elderly vs.
younger; (p<0.
001).
92.
5% (n=889) of the elderly were at high risk of bleeding (PRECISE-DAPT≥25 points), compared to 21.
3% (n=607) of the youngest.
The incidence of BARC 2–5 and BARC 3–5 was 7.
4% and 2.
7% in the elderly compared to 5.
1% and 1.
4% among the younger patients (p<0.
001).
The figure shows the ability of the PRECISE-DAPT score at capturing the risk of BARC 2–5 bleeding (panel A and B), in both age groups.
Using the cut-off point ≥25, the effect in the prediction of BARC 2–5 bleeding and BARC 3–5 did not differ significantly between the elderly and those <75 years: sHR = 1.
9 (95% CI: 1.
2–6.
00) in the elderly vs.
1.
8 (95% CI: 1.
3–2.
5) in the other group (p=0.
99) and sHR = 3.
3 (95% CI: 1.
9–6.
0) vs.
3.
6 (95% CI: 1.
9–6.
7) (p=0.
83), respectively.
There were no significant differences between the elderly and those under 75 years in terms of statistical C values either for BARC 2–5 bleeding (0.
60 vs.
0.
58) or BARC 3–5 bleeding (0.
64 vs.
0.
67).
The score performed well in term of calibration in both groups (all p-values >0.
3).
Conclusion
Although the use of PRECISE-DAPT resulted in classifying the majority of elderly patients at high risk of bleeding and despite exhibiting modest discriminative power, it performed well at classifying patients according to their risk of 1-year out-of-hospital bleeding in both age groups.
PRECISE-DAPT appears to identify the truly low risk patients among the elderly, as compared to the younger group.
Related Results
Performance of PRECISE-DAPT and Age–Bleeding–Organ Dysfunction Score for Predicting Bleeding Complication During Dual Antiplatelet Therapy in Chinese Elderly Patients
Performance of PRECISE-DAPT and Age–Bleeding–Organ Dysfunction Score for Predicting Bleeding Complication During Dual Antiplatelet Therapy in Chinese Elderly Patients
BackgroundRecently, the Age–Bleeding–Organ Dysfunction (ABO) algorithm was recommended by the Asian Pacific Society of Cardiology Consensus as a binary approach to evaluate bleedin...
Prolonging Dual Antiplatelet Therapy Improves Long-term Prognosis in Diabetic Patients Undergoing Complex Percutaneous Coronary Intervention with Drug-eluting Stents
Prolonging Dual Antiplatelet Therapy Improves Long-term Prognosis in Diabetic Patients Undergoing Complex Percutaneous Coronary Intervention with Drug-eluting Stents
Abstract
Background The optimal dual antiplatelet therapy (DAPT) duration after percutaneous coronary intervention (PCI) remains controversial, especially for patients at h...
The effect of co-treatment with DAPT and oxaliplatin on the biological behavior of human ovarian cancer stem cells
The effect of co-treatment with DAPT and oxaliplatin on the biological behavior of human ovarian cancer stem cells
Abstract
To assess the effects of the combination of DAPT and oxaliplatin on the biological behavior of human ovarian cancer stem cells. In vitro cultured human ovarian can...
Early dual antiplatelet therapy versus acetylsalicylic acid monotherapy after CABG: propensity score analysis addressing survival and safety outcomes
Early dual antiplatelet therapy versus acetylsalicylic acid monotherapy after CABG: propensity score analysis addressing survival and safety outcomes
Abstract
Background
There is currently conflicting evidence regarding the security profile and outcomes of dual antiplatelet the...
No Differences in Gastrointestinal Bleeding Risk among Clopidogrel-, Ticagrelor-, or Prasugrel-Based Dual Antiplatelet Therapy
No Differences in Gastrointestinal Bleeding Risk among Clopidogrel-, Ticagrelor-, or Prasugrel-Based Dual Antiplatelet Therapy
The risk for gastrointestinal bleeding from dual antiplatelet therapy (DAPT) with new antiplatelets (prasugrel/ticagrelor) compared to clopidogrel is unclear. Aim: To determine the...
226 DUAL ANTI-PLATELET THERAPY: AUDIT OF COMMUNICATION OF DIAGNOSIS AND DURATION ACROSS PRIMARY AND SECONDARY CARE
226 DUAL ANTI-PLATELET THERAPY: AUDIT OF COMMUNICATION OF DIAGNOSIS AND DURATION ACROSS PRIMARY AND SECONDARY CARE
Abstract
Background
Dual Anti-Platelet Therapy (DAPT) is indicated in vascular disease & duration of treatment depends on fa...
Adherence to dual antiplatelet therapy after coronary stenting: A study conducted at two Vietnamese hospitals
Adherence to dual antiplatelet therapy after coronary stenting: A study conducted at two Vietnamese hospitals
Introduction: Adherence to dual antiplatelet therapy (DAPT) is critical after drug-eluting stent(DES) placement. We aimed to assess patient’s knowledge, rates of DAPT adherence, tr...
Impact of dual antiplatelet non-adherence after percutaneous coronary intervention in patients with or without history of myocardial infarction
Impact of dual antiplatelet non-adherence after percutaneous coronary intervention in patients with or without history of myocardial infarction
Abstract
Funding Acknowledgements
Type of funding sources: None.
OnBehalf
...

